Allergy最新文献

{"title":"Exploring Occupational Asthmagen-Related Asthma Phenotypes: A Cluster Analysis and Machine Learning Study.","authors":"Tzu-Ching Liao, Pei-Chien Tsai, Meng-Chih Lin, Chao-Chien Wu, Hung-Chen Chen, Pei-Shih Chen, Yuan-Chung Lin, Kang-Shin Chen, Tsu-Nai Wang","doi":"10.1111/all.16422","DOIUrl":"https://doi.org/10.1111/all.16422","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142826730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Double‐Blind and Open Food Challenges for the Diagnosis of Food Allergy in Childhood: The ALDORADO Study","authors":"Wouter W. de Weger, Aline. B. Sprikkelman, Catherina. E. M. Herpertz, Gerbrich N. van der Meulen, Judith. M. Vonk, Gerard. H. Koppelman, Arvid. W. A. Kamps","doi":"10.1111/all.16428","DOIUrl":"https://doi.org/10.1111/all.16428","url":null,"abstract":"BackgroundDouble‐blind placebo‐controlled food challenge (DBPCFC) is widely regarded as the “gold standard” to diagnose food allergy. Maximum efforts are made to reduce bias, yet DBPCFCs are costly, time‐, and resource‐intensive. Less demanding open food challenges are increasingly used in clinical practice. However, recommendations regarding the use of these challenges are based on low certainty of evidence, and no comparative studies have been performed using the most recent international food challenge guidelines. We hypothesised that the open food challenge is non‐inferior to DBPCFC in children suspected of allergy to cashew nuts, hazelnuts or peanuts.MethodsA total of 63 children, aged 4 years and older, were included if referred for suspected IgE‐mediated allergy to cashew nut, hazelnut, or peanut. All study participants underwent DBPCFC first, followed by an open food challenge for the same food. Challenge outcomes were assessed by predefined criteria into positive, negative, or inconclusive.ResultsDBPCFC and open food challenge outcomes were the same for 36/41 (87.8%) patients. Sensitivity and specificity of the open food challenge were 0.91 (95% CI 0.79, 1.03) and 0.83 (95% CI 0.63, 1.01), respectively, with an AUC value of 0.87. Eliciting and stop doses were not significantly different between both food challenges.ConclusionThe Diagnostic accuracy of open food challenge is non‐inferior to that of DBPCFC. This finding implies less demanding open food challenges can be implemented for children from the age of 4 years suspected to be cashew nut, hazelnut, or peanut allergic. Further research is necessary to validate our findings and to investigate the diagnostic accuracy for other major food allergens.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"16 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Reduction of FeNO on Anti‐IL5 Biologics Is Associated With Clinical Remission of Severe Asthma","authors":"Marianne Baastrup Soendergaard, Susanne Hansen, Kjell Erik Julius Håkansson, Anna von Bülow, Anne‐Sofie Bjerrum, Johannes Martin Schmid, Sofie Lock Johansson, Linda Makowska Rasmussen, Claus Rikard Johnsen, Barbara Bonnesen Bertelsen, Niels Steen Krogh, Ole Hilberg, Charlotte Suppli Ulrik, Celeste Porsbjerg","doi":"10.1111/all.16425","DOIUrl":"https://doi.org/10.1111/all.16425","url":null,"abstract":"BackgroundIn patients with severe asthma, treatment with anti‐interleukin‐5 (IL‐5) biologics can lead to a reduction in fractional exhaled nitric oxide (FeNO) in some patients. The clinical implications of varying FeNO responses to anti‐IL‐5 biologics remain unclear. This study aims to categorise patients based on their FeNO response to anti‐IL‐5 biologics and evaluate the association of these categories with clinical outcomes.MethodsWe used the Danish Severe Asthma Register (DSAR) to identify the early FeNO response profiles in patients receiving anti‐IL5 biologics. We defined FeNO responders as patients with elevated FeNO levels at baseline and a decrease corresponding to the minimal clinically important difference (MCID) at 4 months of follow‐up and FeNO non‐responders as those who did not experience a decrease.ResultsWe identified 403 patients on anti‐IL5 treatment in DSAR, and 265 (66%) had elevated FeNO levels at baseline. After 4 months of treatment, 151 (57%) patients showed a significant decrease in FeNO levels, and 114 (43%) did not. FeNO responders were more likely to achieve clinical remission of asthma (34% vs. 19%, <jats:italic>p</jats:italic> = 0.01, OR 2.11, CI 1.04, 5.18, <jats:italic>p</jats:italic> = 0.03) than FeNO non‐responders after 12 months of treatment. The higher remission rates in FeNO responders mainly reflected a higher rate of normalisation of lung function.ConclusionsFeNO levels were reduced after anti‐IL5 treatment in a significant proportion of patients treated with anti‐IL5, and this was associated with clinical remission. Early FeNO response to anti‐IL5 could potentially be used as a biomarker to guide management decisions with biologics towards remission of disease in severe asthma.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"14 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28‐Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels","authors":"Coco Dekkers, Nicolaas Zuithoff, Daphne Bakker, Edward Knol, Anne Wevers, Wouter Touwslager, Wianda Christoffers, Petra Prosje, Anneke van Lynden‐van Nes, Paula van Lümig, Marijke Kamsteeg, Albert Jan Oosting, Marie L. A. Schuttelaar, Inge Haeck, Marlies de Graaf, Femke van Wijk, Marjolein de Bruin‐Weller","doi":"10.1111/all.16414","DOIUrl":"https://doi.org/10.1111/all.16414","url":null,"abstract":"Introduction and ObjectivesTralokinumab—a biological that specifically targets interleukin‐13—is one of the newer advanced systemic treatments for patients with moderate‐to‐severe atopic dermatitis (AD). Although safety and efficacy have been shown in phase‐III clinical trials, daily practice data are needed. Therefore, the aim of this study was to evaluate 28‐week safety and effectiveness, serum proteins and total IgE levels in adult AD patients treated with tralokinumab in daily practice.Materials and MethodsData of all adult AD patients who started treatment with tralokinumab and participated in the BioDay registry were collected at baseline, and after 4,16 and 28 weeks of treatment. Clinical efficacy was evaluated by clinical outcome measures, such as the Eczema Area and Severity Index (EASI) as well as patient‐reported outcome measures, such as the numerical rating scale (NRS) for pruritus. Adverse events were evaluated. In a subgroup of patients, 18 proteins as well as total IgE levels were measured in serum.ResultsA total of 84 patients were included, of whom 39 were dupilumab‐naïve (D‐naïve) and 45 were dupilumab non‐naïve (D‐non‐naïve) patients. All primary outcomes significantly improved during 28 weeks of tralokinumab treatment and the probability of achieving EASI ≤ 7 and NRS‐pruritis ≤ 4 was 75.8% (56.9–88.2) and 51.4% (28.0–74.2), respectively. The disease severity‐associated proteins TARC/CCL17 and PARC/CCL18 decreased during treatment, and total IgE levels significantly decreased in the D‐naïve patients. The most reported adverse events were eye disorders (<jats:italic>n</jats:italic> = 24, 28.6%). A total of 23 patients (27.4%) discontinued treatment due to adverse events and/or ineffectiveness, with hair loss being the most common adverse event leading to treatment discontinuation (<jats:italic>n</jats:italic> = 6).ConclusionTralokinumab is an effective treatment for moderate‐to‐severe AD in adult patients, in both dupilumab‐naïve patients and patients who previously failed on dupilumab treatment. The clinical effect is supported by the biological data.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"47 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open‐Label, Phase II Study","authors":"Sayantani B. Sindher, Kari C. Nadeau, R. Sharon Chinthrajah, Jeffrey G. Leflein, Philippe Bégin, Jason A. Ohayon, Punita Ponda, Erik Wambre, Jinzhong Liu, Faisal A. Khokhar, Bolanle Akinlade, Jennifer Maloney, Jamie M. Orengo, Jennifer D. Hamilton, Mohamed A. Kamal, Andrea T. Hooper, Naimish Patel, Kiran Patel, Elizabeth Laws, Leda P. Mannent, Allen R. Radin","doi":"10.1111/all.16404","DOIUrl":"https://doi.org/10.1111/all.16404","url":null,"abstract":"BackgroundPeanut allergy is a potentially life‐threatening food allergy in children. This study explored whether dupilumab, a human monoclonal immunoglobulin (Ig)G4 antibody that blocks the activity of interleukin (IL)‐4/IL‐13, improved safety and desensitization to peanut exposure in children with peanut allergy.MethodsA Phase II, 24‐week, multicenter, single‐arm, open‐label, proof‐of‐concept study was conducted in the USA and Canada (NCT03793608). Children/adolescents with peanut allergy received subcutaneous dupilumab 300 mg (≥ 60 kg) or 200 mg (≥ 20 to &lt; 60 kg) every 2 weeks. The primary endpoint was the proportion of participants who passed a double‐blind placebo‐controlled food challenge (DBPCFC) with ≥ 444 mg (cumulative) of peanut protein at week 24. Secondary endpoints included safety measures (Consortium of Food Allergy Research grading system) and change from baseline in peanut‐specific (ps)‐IgG4, total IgE, and ps‐IgE.ResultsTwenty‐four participants enrolled and received dupilumab: 75.0% were male, 79.2% were white, mean (standard deviation) age was 11.7 (3.3) years. Most (95.8%) participants had not received allergen immunotherapy. Two participants (8.3%) achieved the primary endpoint and passed the DBPCFC at week 24. Fifteen participants (62.5%) reported 66 treatment‐emergent adverse events, all being mild or in moderate intensity. At the week 24 DBPCFC, 8 participants (33.3%) had a grade 2 allergic reaction (no grade 3 or above); 10 (41.7%) used adrenaline as a rescue medication. Dupilumab treatment resulted in a median reduction of total and ps‐IgE of −54% and −49%, respectively, and a 0% change in ps‐IgG4.ConclusionsDupilumab monotherapy treatment for 24 weeks did not improve desensitization to peanut exposure after food challenge.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"100 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genome‐Wide Association Study Reveals a Causal Relationship Between Allergic Rhinitis and Hazelnut Allergy","authors":"Yidan Sun, Judith M. Vonk, Elin T. G. Kersten, Cancan Qi, Aline B. Sprikkelman, Gerard H. Koppelman","doi":"10.1111/all.16411","DOIUrl":"https://doi.org/10.1111/all.16411","url":null,"abstract":"BackgroundLittle is known about the genetics of food allergy (FA) to various allergens and the heterogeneity of FA in adults.ObjectiveWe aimed to investigate genetic susceptibility to FA in an adult population and to assess the association between secondary FA and allergic rhinitis (AR).MethodsFA and allergen‐specific FA were defined based on in‐depth questionnaires and a previously published FA algorithm in the Lifelines. We performed a series of genome‐wide association studies (GWAS) on FA and nine allergen‐specific (e.g., hazelnut) FA in 21,353 adults in Lifelines. Single nucleotide polymorphisms (SNPs) (<jats:italic>p</jats:italic> &lt; 1E‐5) were replicated in a second independent set of 15,518 adults participating in the Lifelines followed by meta‐analysis of the results of the two datasets. We subsequently investigated the causal relationship of AR to FA using Mendelian randomization (MR) analysis.ResultsWe observed co‐occurrence of tree nuts and apple FA, with over 80% of this group also reporting AR. After meta‐analysis, we identified one genome‐wide significant locus near <jats:italic>HLA‐DPA1</jats:italic> associated with self‐reported hazelnut allergy (hazelnutFA), of which the top SNP is rs5025825 (<jats:italic>p</jats:italic> = 2.51E‐9, OR = 1.43). Two‐sample MR indicated that AR is a significant causal risk factor for hazelnutFA (<jats:italic>p</jats:italic><jats:sub>‐IVW</jats:sub> = 5.27E‐10, <jats:italic>β</jats:italic> = 5.90, <jats:italic>p</jats:italic><jats:sub>‐pleiotropy</jats:sub> = 0.46).ConclusionOur questionnaire enabled a large GWAS on self‐reported FA in Dutch adults. We report one novel locus in the human leukocyte antigens (HLA) region associated with hazelnutFA, implying an association with antigen recognition. Our findings genetically link secondary FA to AR in adults.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"200 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy","authors":"R. Sharon Chinthrajah, Sayantani B. Sindher, Kari C. Nadeau, Jeffrey G. Leflein, Jonathan M. Spergel, Daniel H. Petroni, Stacie M. Jones, Thomas B. Casale, Julie Wang, Warner W. Carr, Wayne G. Shreffler, Robert A. Wood, Erik Wambre, Jinzhong Liu, Bolanle Akinlade, Amanda Atanasio, Jamie M. Orengo, Jennifer D. Hamilton, Mohamed A. Kamal, Andrea T. Hooper, Kiran Patel, Elizabeth Laws, Leda P. Mannent, Daniel C. Adelman, Anoshie Ratnayake, Allen R. Radin","doi":"10.1111/all.16420","DOIUrl":"https://doi.org/10.1111/all.16420","url":null,"abstract":"BackgroundPeanut allergy is a common, life‐threatening food allergy in children. We evaluated whether dupilumab, which blocks the activity of interleukin (IL)‐4/IL‐13, enhances the efficacy of oral immunotherapy (OIT) AR101 in pediatric patients with peanut allergy.MethodsA Phase II, multicenter, randomized, double‐blind study was conducted in the USA (NCT03682770) in pediatric patients (6–≤ 17 years old) with confirmed peanut allergy. Patients were randomized 2:1 to receive dupilumab + OIT or placebo + OIT during a 28–40‐week up‐dosing period. Patients in the dupilumab + OIT group were re‐randomized 1:1 and received dupilumab + OIT or placebo + OIT during 24‐week OIT maintenance, undergoing a 2044 mg (cumulative) of peanut protein double‐blind, placebo‐controlled food challenge (DBPCFC) following up‐dosing, maintenance, and at 12‐week post‐treatment follow‐up.ResultsThe study enrolled 148 patients, 123 of whom were included in the modified full analysis set, with a mean age of 11.1 years. Dupilumab + OIT treatment (<jats:italic>n</jats:italic> = 84) led to a 20.2% increase (<jats:italic>p</jats:italic> &lt; 0.05) in the number of patients who passed a DBPCFC to 2044 mg (cumulative) of peanut protein following the up‐dosing period versus placebo (OIT alone, <jats:italic>n</jats:italic> = 39). Following the OIT maintenance period, continuous dupilumab treatment improved the number of patients who passed a DBPCFC to 2044 mg (cumulative) of peanut protein versus patients continuously on OIT alone (16.6% difference [95% CI −9.7, 42.8], <jats:italic>p</jats:italic> = 0.2123). Safety was consistent with known dupilumab safety profile.ConclusionsDupilumab provided a modest increase efficacy of OIT in children and adolescents with peanut allergy, though it did not provide protection against OIT‐related anaphylaxis.Trial Registration<jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"http://clinicaltrials.gov\">ClinicalTrials.gov</jats:ext-link> identifier: NCT03793608","PeriodicalId":122,"journal":{"name":"Allergy","volume":"75 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"T Cells Induce Prolonged Downregulation of Barrier Molecules in a Mouse Model of Allergic Contact Dermatitis","authors":"Helen Vaher, Anne‐Sofie Ø. Gadsbøll, Alexandra T. Seibel, Martin Kongsbak‐Wismann, Rebecca K. D. Lohmann, Veronika Mraz, Anders B. Funch, Mia H. Jee, Niels Ødum, Anders Woetmann, Carsten Geisler, Charlotte M. Bonefeld","doi":"10.1111/all.16421","DOIUrl":"https://doi.org/10.1111/all.16421","url":null,"abstract":"BackgroundDysfunction of the skin barrier is regarded as a key event in the initiation and progression of inflammatory skin diseases. In many cases of allergic contact dermatitis (ACD), epidermal‐resident memory CD8<jats:sup>+</jats:sup> T (T<jats:sub>RM</jats:sub>) cells play a central role in the immune response to contact allergens. However, if and how allergen‐specific CD8<jats:sup>+</jats:sup> T<jats:sub>RM</jats:sub> cells affect the expression of skin barrier molecules is not known.MethodsThe expression level of skin barrier molecules was determined by RT‐qPCR and immunofluorescence in a mouse model of ACD. The role of CD8<jats:sup>+</jats:sup> T cells on the expression of skin barrier molecules was investigated by depletion of CD8<jats:sup>+</jats:sup> cells. Human primary keratinocytes were used to assess the direct effect of IFN‐γ and contact allergen on their expression of skin barrier molecules.ResultsSensitization with the contact allergen 1‐fluoro‐2,4‐dinitrobenzene (DNFB) resulted in epidermal accumulation of CD8<jats:sup>+</jats:sup> T<jats:sub>RM</jats:sub> cells and prolonged upregulation of <jats:italic>Ifng</jats:italic> and downregulation of keratin 5 (<jats:italic>Krt5</jats:italic>) and <jats:italic>Krt14</jats:italic> even after complete macroscopic remission of the inflammatory response. Challenge with DNFB lead to an additionally rapid downregulation of <jats:italic>Krt5</jats:italic> and <jats:italic>Krt14</jats:italic> and the downregulation of several other skin barrier molecules. Depletion of CD8<jats:sup>+</jats:sup> cells abolished both the prolonged and rapid downregulation of skin barrier molecules. In keratinocytes, IFN‐γ and contact allergen synergistically down‐regulated the expression of KRT5 and KRT14.ConclusionCD8<jats:sup>+</jats:sup> T<jats:sub>RM</jats:sub> cells contribute to a prolonged reduction in the expression of skin barrier molecules, which might exacerbate allergen permeation and the inflammatory response during succeeding exposures of the skin to allergens and antigens.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"21 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Presence and Pathogenic Roles of M(IL-33 + IL-2) Macrophages in Allergic Airway Inflammation.","authors":"Han Guo, Yang Zhao, Zhaoqi Zhang, Yanan Xu, Yifang Chen, Tong Lei, Yong Zhao","doi":"10.1111/all.16430","DOIUrl":"https://doi.org/10.1111/all.16430","url":null,"abstract":"<p><strong>Background: </strong>Macrophages, one of the most abundant immune cells in the lung, have drawn great attention in allergic asthma. Currently, most studies emphasize alternative activated (M2) polarization bias. However, macrophage function in allergic asthma is still controversial. Interleukin (IL)-9 contributes to the development and pathogenesis of allergic airway inflammation. We sought to investigate the IL-9-producing macrophage and its role in allergic asthma.</p><p><strong>Methods: </strong>The model of ovalbumin (OVA)-induced allergic airway inflammation was employed to evaluate IL-9 production in macrophages of lung tissues. We used 22 cytokines or stimuli to screen for IL-9-producing mouse macrophage subset in vitro. Real-time PCR, flow cytometry, ELISA, and RNA-seq to explore the subset. Conditional IL-33 receptor knockout (Lyz-ST2KO) mice and cellular adoptive transfer experiment were used to characterize the potential roles of M(IL-33 + IL-2) in allergic asthma.</p><p><strong>Results: </strong>We identified a unique pathogenic IL-9-producing macrophage in OVA-induced allergic airway inflammation. We found that only IL-33 significantly induced IL-9 production in mouse macrophages, and IL-2 collaborated with IL-33 to promote IL-9 production, referred to as M(IL-33 + IL-2). Importantly, human monocyte-derived macrophages produced IL-9 after IL-33 and IL-2 stimulation. Using Lyz-ST2KO mice and adoptive transfer of M(IL-33 + IL-2), we found that M(IL-33 + IL-2) significantly promoted pathogenesis in OVA-induced allergic airway inflammation. M(IL-33 + IL-2) has a distinctive gene expression profile with high expression of IL-9, IL-5, and IL-13 and its polarization is dependent on JAK2-STAT3-IRF1 pathway.</p><p><strong>Conclusions: </strong>The identification of M(IL-33 + IL-2) subset extends the diversity and heterogeneity of macrophage subsets and may offer novel therapeutic strategies for the treatment of allergic inflammation.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142816740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal Associations Between Chronic Spontaneous Urticaria and Thyroid Function Indicators on Different Ethnic Groups: A Bidirectional Two-Sample Mendelian Randomization Analysis.","authors":"Lijun Deng, Yuxu Yao, Zhenzhong Lu, Ping Xia, Tingting Yu, Hui Shen, Jiang Ji, Qingqing Jiao","doi":"10.1111/all.16400","DOIUrl":"https://doi.org/10.1111/all.16400","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142816737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}